

---

## Cantargia Q4 2023 - Progress with CAN10 and in PDA

Redeye comments on Cantargia's Q4 report, which contains progress with CAN10 and with nadunolimab in pancreatic cancer, now ready for a phase IIb trial.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Cantargia Q4 2023 - Progress with CAN10 and in PDA](#)